Nasvac: A Novel Warrior in a Strategic Battle for the Global South
DOI:
https://doi.org/10.14738/bjhr.1204.19122Keywords:
Nasvac, chronic hepatitis B, immunetherapyAbstract
Chronic hepatitis B virus (HBV) infection remains one of the most significant global health challenges, with approximately 1 million deaths annually due to complications such as cirrhosis, liver failure, and hepatocellular carcinoma (HCC). Despite advances in the field of therapies, achieving a functional cure-defined as sustained loss of hepatitis B surface antigen (HBsAg) and undetectable HBV DNA-remains elusive. Current treatments, including nucleos(t)ide analogs (NUCs) and pegylated interferon (PegIFN), have limitations in efficacy, safety, and effectiveness, particularly in low- and middle-income countries where the burden of HBV is highest. In this context, therapeutic vaccination emerges as a promising strategy, leveraging the immune system to mount a coordinated and sustained attack against HBV. Nasvac, a novel therapeutic vaccine that will enter in real-life studies after a successful registration and post-marketing phase IV studies, represents a paradigm shift in the fight against CHB, offering a multi-pronged approach that activates both innate and adaptive immunity. This article revisit the current situation in the Global South in respect of Chronic Hepatitis B and explores the rationale and mechanisms of Nasvac, compares it to current therapies, and draws parallels to military strategy, ultimately calling for a global focus on the "war against the pathogen".
References
World Health Organization. Global Hepatitis Report 2021. Geneva: WHO; 2021. Available from: https://www.who.int/publications/i/item/9789240027077.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015 Oct 17;386(10003):1546-55. doi: 10.1016/S0140-6736(15)61412-X.
Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development? J Hepatol 2022;76:1249–1262. doi: 10.1016/j.jhep.2021.11.024.
Wong, G.L., Gane, E., Lok, A.S.F. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development? J Hepatol. 2022;76(6):1249-1262. doi:10.1016/j.jhep.2021.11.024.
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398. doi:10.1016/j.jhep.2017.03.021.
Aguilar J.C., Aguiar J.A., Akbar S.M.F. Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B. Vaccines. 2022;10(12):2087. doi:10.3390/vaccines10122087.
Aguilar, J.C., Akbar, S.M.F., Al-Mahtab, M., Khan, M.S.I., Guzman, C.A., Fernandez, G., Aguiar, J.A., Michel, M.L., Bourgine, M., Marrero, M.A., Trittel, S., Ebensen, T., Riese, P., Le Grand, R., Herate, C., Mauras, A., Yoshida, O., Hiasa, Y., Penton, E., Guillen, G.E. HeberNasvac: Development and Application in the Context of Chronic Hepatitis B. Euroasian Journal of Hepato-Gastroenterology. 2024;14(2):221-237. doi:10.5005/jp-journals-10018-1457.
Wong G.L., Lampertico P. Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB—Is one NUC better than the other? J Hepatol. 2019;71(3):453-455. doi:10.1016/j.jhep.2019.05.017.
Akbar S.M., Yoshida O., Chen S., Aguilar J.C., Abe M., Matsuura B., Hiasa Y., Onji M. Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface Ag and core antigen for treating chronic HBV infection. Antiviral Ther. 2010;15(6):887-895. doi:10.3851/IMP1637. 121
Lobaina Y., Hardtke S., Wedemeyer H., Aguilar J.C., Schlaphoff V. In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol. 2015;63(2):320-327.doi:10.1016/j.molimm.2014.08.003.
Al-Mahtab M, Akbar SM, Aguilar JC, Uddin MH, Khan MS, Rahman S. Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B. Hepatol Int. 2013;7(4):981-989. doi:10.1007/s12072-013-9486-4.
Bourgine M., Crabe S., Lobaina Y., Guillen G., Aguilar J.C., Michel M.L. Nasal route favors the induction of CD4+ T cell responses in the liver of HBV-carrier mice immunized with a recombinant hepatitis B surface- and core-based therapeutic vaccine. Antiviral Res. 2018;153:23-32. doi:10.1016/j.antiviral.2018.02.019.
Fleites Y.A., Aguiar J., Cinza Z., Bequet M., Marrero E., Vizcaíno M., Esquivel I., Diaz M., Sin-Mayor A., Garcia M., Martinez S.M., Beato A., Galarraga A.G., Mendoza-Mari Y., Valdés I., García G., Lemos G., González I., Canaán-Haden C., Figueroa N., Oquendo R., Akbar S.M.F., Mahtab M.A., Uddin M.H., Guillén G.E., Muzio V.L., Pentón E., Aguilar J.C.. HeberNasvac, a therapeutic vaccine for chronic hepatitis B, stimulates local and systemic markers of innate immunity: Potential use in SARS-CoV-2 post-exposure prophylaxis. Euroasian J Hepato-Gastroenterol. 2021;11(1):59-70. doi:10.5005/jp-journals-10018-1344.
Guillen G.E. and Aguilar J.C. The Cuban approach for Hepatitis B elimination. Long term evaluation of HBsAg levels in the serum of samples from chronic hepatitis b patients treated with HeberNasvac in the Phase IV Clinical Trial, preliminary results. In proceedings of: APASL 2025, Oral Presentation at HBV elimination workshop. Beijing, China (26-30 Apr 2025).
Aguilar J.C. On the future of therapeutic vaccination in chronic hepatitis B. Future Sci OA. 2019;5(7):FS0426. doi:10.2144/fsoa-2019-0104.
Wong GL, Lampertico P. Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB—Is one NUC better than the other? J Hepatol. 2019;71(3):453-455. doi:10.1016/j.jhep.2019.05.017.
Lok A.S., McMahon B.J. Chronic hepatitis B: Update 2009. Hepatology. 2009;50(3):661-662. doi:10.1002/hep.23190.
Buti M., Tsai N., Petersen J., Flisiak R., Gurel S., Krastev Z., Aguilar Schall R., Flaherty J.F., Martins E.B., Charuworn P., Kitrinos K.M., Subramanian G.M., Gane E., Marcellin P. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60(5):1457-1464. doi:10.1007/s10620-014-3486-7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Julio Cesar Aguilar Rubido, Mamun Al Mahtab, Sheikh Mohammad Fazle Akbar
This work is licensed under a Creative Commons Attribution 4.0 International License.
